Organigram Global Inc.

OGI Healthcare Drug Manufacturers Specialty & Generic

Organigram Global Inc.’s revenue for fiscal 2025 (year ended September 2025) was $185.3 million, up 57.7% from fiscal 2024. In the quarter to June 2026, revenue grew 49.3%, EPS grew 1,966.7% and free cash flow fell 192.3%, each against the same quarter a year earlier.

0.93 0.00 0.00%
Market cap
$131.4M
P/E
2.0×
Fwd P/E
11.4×
Dividend yield
—
F-score
5/9
Altman Z
0.22
Beneish M
−1.82
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 4 5 5

+8 more TTM periods

ROE
20.20% (6.34%) 5.25% (7.46%)
ROA
12.70% (4.56%) 3.60% (5.05%)
ROIC
(1.53%) (3.94%) (1.51%) (3.61%)
Return on Tangible Assets
29.94% (8.37%) 6.35% (8.79%)
Average Days of Receivables
104.53 71.65 65.26 91.34
Free Cash Flow per Share
(0.16) (0.12) (0.20) (0.14)
Free Cash Flow
(21.14) (15.72) (26.36) (17.54)
Other line items

Show all line items

Columns are period end dates